NYSE · ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES · LARGE CAP
Zimmer Biomet Holdings, Inc. ZBH
19 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$8.2B
▲ 7.2% vs FY2024
EPS · FY25
$3.55
Dividend / sh · FY25
$0.96
Payout · FY25
27%
ROE · FY25
5.6%
Net margin · FY25
8.6%
Dividend coverage
3.7×
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 8.2B
Revenue, FY2025 · full 19-year series below
Revenue
Net income
9 cents of every revenue dollar became profit this year.
Per share
USD 3.55
Diluted EPS, FY2025
EPS
Dividend
Earnings covered the dividend 3.7 times — the rest stayed in the company.
Profitability
5.6%
Return on equity, FY2025
ROE
Operating margin13.3%
Net margin8.6%
Return on assets3.2%
Each USD of equity produced 6 cents of profit this year.
Returned to shareholders
USD 677.3M
returned in FY2025 · dividends + net buybacks
Dividends paidUSD 190.3M
Net buybacksUSD 487.0M
Share of profit96.1%
Consecutive raises—
USD 190.3M in dividends and USD 487.0M in buybacks — 96% of the year's profit went back to shareholders.
Growth
+6.1% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+5.9%
+6.1%
+3.2%
+4.6%
Net income
+45.0%
+17.0%
+1.1%
EPS, diluted
+47.8%
+16.5%
+1.2%
Dividend / share
+0.0%
+0.0%
+0.9%
Returned to shareholders
+27.4%
+27.8%
+8.2%
+2.0%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
—
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 23.1B
total assets, end of FY2025
Total assetsUSD 23.1B
EquityUSD 12.7B
CashUSD 591.9M
Gross debtUSD 7.5B
Net debtUSD 6.9B
Current ratio1.98×
Net debt stands at 55% of equity.
History
19 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
Revenue $B
8.2
7.7
7.4
6.9
6.8
6.1
8.0
7.9
7.8
7.7
6.0
4.7
4.6
4.5
4.5
4.2
4.1
4.1
3.9
Operating income $B
1.1
1.3
1.3
0.7
0.9
0.1
1.1
0.0
0.8
0.8
0.5
1.0
1.1
1.0
1.0
0.9
1.0
1.1
1.1
EBITDA $B
2.2
2.3
2.2
1.6
1.8
1.0
2.1
1.1
1.9
1.9
1.2
1.4
1.4
1.4
1.4
1.3
1.4
1.4
1.4
Income tax $B
0.1
0.1
0.0
0.1
0.1
−0.1
−0.2
0.1
−1.3
0.1
0.0
0.2
0.2
0.2
0.2
0.3
0.3
0.3
0.4
Net income $B
0.7
0.9
1.0
0.2
0.4
−0.1
1.1
−0.4
1.8
0.3
0.1
0.7
0.8
0.8
0.8
0.6
0.7
0.8
0.8
EPS, diluted $
3.55
4.43
4.88
1.10
1.91
−0.67
5.47
−1.86
8.90
1.51
0.77
4.20
4.54
4.29
4.03
2.97
3.32
3.72
3.26
Dividend / sh $
0.96
0.96
0.96
0.96
0.96
0.96
0.96
0.96
0.96
0.96
0.88
0.88
0.80
0.54
0.18
·
·
·
·
Payout %
27
22
20
87
50
−143
17
−51
11
62
107
20
17
13
·
·
·
·
·
ROE %
5.6
7.2
8.4
1.9
3.2
−1.1
9.6
−3.3
16.9
3.1
1.8
11.2
12.8
13.3
13.5
10.5
12.7
15.0
·
Shares out B
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
63 of 63
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed